Selexis CHO Cells in Suspension-1

Selexis SUREtechnology Modular Approach for Expression of Diverse Array of Biomolecules

May 2021

Pierre-Alain Girod, PhD, Chief Science Officer

Technology platforms are integral to the design, development and commercialization of recombinant biotherapeutics. We developed a versatile platform - SUREtechnology – that facilitates the effective combination of polypeptides. It provides convenience to produce complex protein scaffolds including antibodies, bispecifics, viruses, Fc-fusions, cytokines, and vaccine antigens. By enabling a robust expression of transgenes and enhanced throughput it enables the combination with metabolism interfering proteins to ease the expression of difficult-to-express scaffolds.

WATCH WEBINAR

Ready To Learn More?

Access the Webinar!

 
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

April 17, 2023

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

Read More
March 21, 2023

KBI Releases Inaugural FIH Batch at Geneva Five Months After Opening

Read More

Copyright© 2023 Selexis SA. All Rights Reserved.